Thousands of Medicare Beneficiaries Lose Drug Coverage Over Unpaid Premiums Following Plan Price Increases

Tens of thousands of Medicare beneficiaries have lost their prescription drug coverage after failing to pay premiums on plans they previously believed were free. The disenrollments primarily affected members of Wellcare’s Value Script plan, where premiums rose from zero to nominal amounts that many enrollees did not realize they owed. This mass loss of coverage poses a significant risk to the pharmaceutical sector as patients lose insurance-subsidized access to critical medications, potentially leading to decreased adherence and increased reliance on discount programs.

Centene Corporation’s subsidiary, Wellcare, reportedly terminated coverage for approximately 140,000 members of its Value Script drug plan in April due to delinquent payments. The Value Script plan, which serves nearly 6 million customers, had previously offered $0 monthly premiums in many regions, but price adjustments in 26 states and Washington, D.C., resulted in new monthly charges. According to KFF Health News, some beneficiaries were dropped for owing as little as $8.10 over three months, while others lost coverage over balances as low as $28.80. Under current Medicare regulations, many of these individuals are now barred from re-enrolling in a drug plan until the next enrollment cycle for the 2027 coverage year.

The loss of coverage has immediate implications for pharmaceutical utilization and patient health outcomes, as nearly 90% of Medicare beneficiaries take at least one prescription drug. For example, patients relying on high-cost maintenance medications like the blood thinner Xarelto face out-of-pocket costs as high as $1,800 for a 90-day supply without insurance. While approximately 40,000 of those disenrolled may qualify for immediate re-enrollment through the "Extra Help" financial assistance program, the remaining 100,000 face a significant gap in coverage. This disruption threatens medication adherence for a population where nearly half of the members live with four or more chronic health conditions that can cause functional or cognitive impairments.

Industry analysts and state officials warn that this trend could expand, with thousands more beneficiaries in 32 states potentially facing similar disenrollments in the coming year as insurers adjust pricing strategies. Although the Centers for Medicare & Medicaid Services (CMS) declined to release specific plan-level disenrollment data, officials from Nevada, West Virginia, and Washington confirmed the scale of the issue. Sarah Baiocchi, a senior vice president at Centene, acknowledged that many members experienced premiums for the first time in several years. For the pharmaceutical industry, these administrative disenrollments represent a volatile shift in the payer landscape, potentially shifting volume from traditional Part D coverage to cash-pay discount platforms like GoodRx.